{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:57:21Z","timestamp":1781308641956,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128424","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:12:43Z","timestamp":1773958363000},"page":"128424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18\u00a0years and older: an international, multicentre, randomized, double blinded phase 3 trial"],"prefix":"10.1016","volume":"79","author":[{"given":"Adora","family":"Rooyakkers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro E.","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo M.","family":"Ruiz-Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamer","family":"Ikram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Ra\u00fal Mu\u00f1oz","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Sued","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry A.","family":"Lioznov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitalina","family":"Dzutseva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghazala","family":"Parveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Zubkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Langley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Barreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Whittle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128424_bb0005","unstructured":"WHO. COVID-19 dashboard.2024;https:\/\/data.who.int\/dashboards\/covid19\/cases (accessed Sept 7, 2024)."},{"key":"10.1016\/j.vaccine.2026.128424_bb0010","author":"WHO"},{"key":"10.1016\/j.vaccine.2026.128424_bb0015","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41541-024-00809-z","article-title":"Exploring the future adult vaccine landscape\u2014crowded schedules and new dynamics","volume":"9","author":"Jones","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.128424_bb0020","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3390\/v15091786","article-title":"COVID-19 vaccines over three years after the outbreak of the COVID-19 epidemic","volume":"15","author":"Zasada","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2026.128424_bb0025","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/S0140-6736(20)30798-4","article-title":"COVID-19 clinical research coalition. Global coalition to accelerate COVID-19 clinical research in resource-limited settings","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128424_bb0030","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/S1473-3099(20)30773-8","article-title":"What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2","volume":"21","author":"Hodgson","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128424_bb0035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128424_bb0040","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","volume":"395","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128424_bb0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0140-6736(21)02753-7","volume":"399","author":"Halperin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128424_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1229716","article-title":"Vaccine efficacy against SARS-CoV-2 for Pfizer BioNTech, Moderna, and AstraZeneca vaccines: a systematic review","volume":"11","author":"Reynolds","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2026.128424_bb0055","unstructured":"National Center for biotechnology information (NCBI) Genome Project 2020; https:\/\/www.ncbi.nlm.nih.gov\/nuccore\/NC_045512.2."},{"key":"10.1016\/j.vaccine.2026.128424_bb0060","author":"WHO"},{"key":"10.1016\/j.vaccine.2026.128424_bb0065","article-title":"Immunogenicity, safety, and immune persistence of one dose of SARS-CoV-2 recombinant adenovirus type-5 vectored vaccine in children and adolescents aged 6-17 years: an immunobridging trial","volume":"12","author":"Han","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2026.128424_bb0070","author":"International Vaccine Access Center (Johns Hopkins Bloomberg School of Public Health), WHO, Coalition for Epidemic Preparedness Innovations"},{"key":"10.1016\/j.vaccine.2026.128424_bb0075","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.str.2025.02.009","article-title":"Molecular basis of Ad5-nCoV vaccine-induced immunogenicity","volume":"33","author":"Dong","year":"2025","journal-title":"Structure"},{"key":"10.1016\/j.vaccine.2026.128424_bb0080","unstructured":"WHO. Tracking SARS-CoV-2 variants. 2023; https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants (accesssed Jul 2023)."},{"key":"10.1016\/j.vaccine.2026.128424_bb0085","unstructured":"WHO. Cov-Lineages. 2023; https:\/\/cov-lineages.org\/lineage_list.html (accessed July 2023)."},{"key":"10.1016\/j.vaccine.2026.128424_bb0090","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41564-021-01053-0","article-title":"Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario","volume":"7","author":"Nasreen","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2026.128424_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48272-5","article-title":"Substitution spectra of SARS-CoV-2 genome from Pakistan reveals insights into the evolution of variants across the pandemic","volume":"13","author":"Ashraf","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128424_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0001896","article-title":"Tracking SARS-CoV-2 variants through pandemic waves using RT-PCR testing in low-resource settings","volume":"3","author":"Nasir","year":"2023","journal-title":"PLoS Glob Public Health"},{"key":"10.1016\/j.vaccine.2026.128424_bb0105","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final analysis of efficacy and safety of single-dose Ad26. COV2 S","volume":"386","author":"Sadoff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128424_bb0110","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","article-title":"Efficacy, safety, and immunogenicity of a booster regimen of Ad26. COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Hardt","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128424_bb0115","article-title":"Protection against COVID-19 hospitalisation conferred by primary-series vaccination with AZD1222 in non-boosted individuals: first vaccine effectiveness results of the European COVIDRIVE study and meta-regression analysis","volume":"31","author":"Meeraus","year":"2023","journal-title":"Lancet Reg Health"},{"key":"10.1016\/j.vaccine.2026.128424_bb0120","doi-asserted-by":"crossref","DOI":"10.1172\/JCI160565","article-title":"Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months","volume":"132","author":"Sobieszczyk","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2026.128424_bb0125","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMoa2113017","article-title":"Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase","volume":"385","author":"El Sahly","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128424_bb0130","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2026.128424_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106700","article-title":"COVID-19 vaccines: considering sex differences in efficacy and safety","volume":"115","author":"Jensen","year":"2022","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.vaccine.2026.128424_bb0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128424_bb0145","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","article-title":"Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia","volume":"397","author":"Logunov","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.128424_bb0150","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.53845","article-title":"Reports of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination in the United States","volume":"6","author":"Abara","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128424_bb0155","article-title":"Guillain-Barre syndrome following COVID-19 vaccines: a review of literature","volume":"14","author":"Yu","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2026.128424_bb0160","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600232X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2600232X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:50:33Z","timestamp":1781308233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2600232X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"alternative-id":["S0264410X2600232X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128424","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relative efficacy, safety, and immunogenicity analysis of two doses versus one dose of recombinant coronavirus vaccine (adenovirus type 5 vector) in adults 18\u00a0years and older: an international, multicentre, randomized, double blinded phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128424"}}